KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

Krazati (adagrasib) - BMS

Lumakras (sotorasib) - Amgen

http://www.ncbi.nlm.nih.gov/pubmed/42707601

Haily Liduin Koyou; Liyana Najwa Binti Inche Mat; Mohd Hazmi Bin Mohamed; Mohd Nazil Salleh; Muhammad Evy Prastiyanto; Nurul Aini Binti Ahmad; Siddarth Raajasekar; Vasudevan Ramachandran; Venkataramanan Swaminathan

Sep 9, 2026